Big Vertex bonuses seem defensible to me

Is that for me?

Is that for me?

The Boston Globe devoted its top story this morning to criticizing Vertex Pharmaceuticals for paying $54 million in retention bonuses to top executives (Cystic fibrosis drug could bring millions to executives. Critics decry plan to compensate executives if costly new drug is profitable.) The Globe story argues that the bonuses are undeserved, unnecessary, and harmful to patients.

Thankfully, the story includes enough facts so that a perceptive reader can draw their own conclusions. Here’s my take:

  • The bonuses are performance based. They will only be paid if the company reaches profitability, which has taken 25 years to achieve. Profitability is key for the long-term success of Vertex and it’s reasonable for executives of this company to have that as an explicit, public goal
  • The new drug that could take Vertex to profitability is likely to offer major benefits to cystic fibrosis patients, enabling them to live longer and enjoy a better quality of life. We’re not talking about a toenail fungus or “me-too” treatment here
  • Vertex management is delivering returns to shareholders: more than a $15 billion increase in value in the past year. The bonuses are small compared to that
  • There is a rationale for retention bonuses, because these executives are attractive to others hoping to emulate Vertex’s success

Of course there are other important issues here: drug pricing, the increasing gap between the richest and everyone else, cost of drug development, government involvement in healthcare, etc. But attacking this particular bonus plan strikes me as a distraction and not worthy of the attention the Globe is providing.

Image courtesy of iosphere at FreeDigitalPhotos.net

By healthcare business consultant David E. Williams, president of Health Business Group.

2 thoughts on “Big Vertex bonuses seem defensible to me

  1. Dr Jennifer Bolen

    ” hundreds of thousands of dollars a year per patient”
    Every dollar in profit to that company was paid for by taxpayers and patients – they hardly deserve that level of compensation on the backs of the most vulnerable part of our population

    Reply
  2. Pingback: What’s the difference between New York and Boston? | Health Business Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s